Authorization

Varian Forms FlashForward Consortium to Study Ultra-high Dose Rate Cancer Treatments with Protons

PALO ALTO, Calif., Oct. 20, 2018 /PRNewswire/ --A To expand the encouraging preclinical and translational research already conducted by Varian (NYSE: VAR) and two of its clinical partners, Maryland Proton Treatment Center and Cincinnati Children's/UC Health Proton Therapy Center, on the value of ultra-high dose rate proton therapy for the treatment of cancer, the company has formed the FlashForwarda?? Consortium. With an initial thirteen members, the consortium is focused on preclinical research, clinical implementation and advocacy efforts of Flash therapy. The initial FlashForward Consortium members are:

University of Maryland Department of Radiation Oncology



Cincinnati Children's/UC Health Proton Therapy Center



Danish Centre for Particle Therapy



Holland Particle Therapy Centre



New York Proton Center



Penn Medicine



The Christie Proton Therapy Centre



University College London



Proton International at the University of Alabama at Birmingham



Emory Proton Therapy Center



Paul Scherrer Institute



Sylvester Comprehensive Cancer Center Proton Therapy



VU University Medical Center Amsterdam

Flash therapy is a non-invasive treatment using an external beam delivered in high doses, at ultra-high speeds (less than 1 second), and in one to three sessions. This new therapy represents an exciting and potentially promising new direction in the treatment of cancer. Working groups in the FlashForward Consortium will help identify preclinical study design for understanding this therapy, develop and share protocols that will enable a safe and quality clinical start for new users, and assist with regulatory and advocacy efforts."We are very excited about the initial preclinical research that has been done on Flash therapy and the potential for a major breakthrough in cancer care," said Dee Khuntia, MD, chief medical officer, Varian. "Varian's preclinical results have shown significantly reduced toxicities to healthy tissues while maintaining excellent tumor control and thereby enhancing the therapeutic ratio. We look forward to working closely with the members of the FlashForward Consortium and taking a big step forward in the fight against cancer.""As a world leader in radiation protection science we are excited about the early results. We applaud Varian for its innovative approach and partnering with the Maryland Proton Treatment Center on this groundbreaking research," said William F. Regine, MD, FACR, FACRO, Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology University of Maryland School of Medicine, Executive Director, Maryland Proton Treatment Center.For more information, visit www.varian.com/flashforward. About Varian
Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world.A For more information, visit https://www.varian.com and follow @VarianMedSys on Twitter.Press ContactMark Plungy
Director, Public Relations
+1 (650) 424-5630
mark.plungy@varian.comInvestor Relations ContactJ. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
investors@varian.comA 
Varian Forms FlashForward Consortium to Study Ultra-high Dose Rate Cancer Treatments with Protons
View original content:https://www.prnewswire.com/news-releases/varian-forms-flashforward-consortium-to-study-ultra-high-dose-rate-cancer-treatments-with-protons-300734661.htmlSOURCE Varian
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2019    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
28293031